Board ReviewInternal medicineComparison

CABG vs PCI on Step 2 CK: The Revascularization Decision, Step by Step

When the 2021 and 2025 ACC/AHA guidelines favor bypass surgery over stenting: left main disease, diabetes, low ejection fraction, ACS and shock.

Step 2 CK outlineCardiovascular SystemClinical InterventionsMixed ManagementMedicineSurgery

A cardiac catheterization lab with the C-arm over the table
AI-generated image
Contents
  1. The revascularization algorithm
  2. The trials behind the answers
  3. Acute coronary syndromes
  4. Clue in the stem, next best step
  5. Where students lose points
  6. Practice question
  7. 60-second recall
  8. Sources

A revascularization question gives a coronary angiogram in words (left main stenosis, three-vessel disease, a diabetic patient, an ejection fraction) and asks what comes next: bypass surgery, a stent, or no procedure at all. Three facts usually decide it: is this an acute coronary syndrome or stable disease, how complex is the anatomy, and does the patient have diabetes or a low ejection fraction.

The revascularization algorithm

  1. Acute or stableSTEMI needs reperfusion now: primary PCI of the culprit artery. Stable ischemic heart disease starts with guideline-directed medical therapy; the question is whether a procedure adds survival or symptom relief.
  2. Left main diseaseSignificant left main stenosis: CABG is recommended to improve survival (class 1). PCI is a reasonable alternative in selected patients whose anatomy is of low to intermediate complexity (class 2a).
  3. Low ejection fractionMultivessel disease with LVEF of 35% or less: CABG improves survival (class 1), based mainly on the STICH extension.
  4. DiabetesMultivessel disease in a patient with diabetes who can have surgery: CABG with a left internal mammary artery graft to the LAD is preferred over PCI (class 1), based on FREEDOM. PCI is an option for poor surgical candidates.
  5. Anatomic complexityComplex multivessel disease (SYNTAX score above 33): CABG is reasonable for a survival benefit over PCI. With less complex anatomy, CABG and PCI give similar results, and the heart team decides with the patient.
  6. Normal ejection fraction, no diabetes, no left mainRevascularization for survival is only class 2b in three-vessel disease with normal LVEF. It can reduce cardiac death, spontaneous MI and urgent revascularization (class 2a), and it relieves angina that persists on medical therapy.
  7. One or two vessels, LAD spared, normal LVEFPCI to improve survival is not recommended (class 3). Treat medically and revascularize for symptoms.

The 2021 downgrade for three-vessel disease with normal LVEF was driven largely by the ISCHEMIA trial and remains disputed: the cardiac surgery societies (STS and AATS) did not endorse that recommendation, arguing that ISCHEMIA was weighted too heavily. Exam questions follow the guideline.

The trials behind the answers

TrialPopulationResultWhat it changed
FREEDOM (2012)Diabetes with multivessel CADCABG lowered the combined rate of death, MI and stroke compared with drug-eluting stents, with more strokes after CABGCABG is preferred in diabetic multivessel disease
STICH extension (2016)Ischemic cardiomyopathy, LVEF 35% or lessCABG plus medical therapy lowered 10-year all-cause mortality compared with medical therapy aloneCABG for multivessel disease with low LVEF
ISCHEMIA (2020)Stable CAD with moderate or severe ischemia, excluding left main disease and LVEF below 35%An initial invasive strategy did not reduce ischemic events or death over a median of 3.2 years; angina improvedMedical therapy first for most stable patients
CULPRIT-SHOCK (2017)Acute MI with cardiogenic shock and multivessel diseaseCulprit-only PCI did better than immediate multivessel PCIRoutine non-culprit PCI in shock is harmful

Acute coronary syndromes

  • STEMI: primary PCI of the culprit artery. If PCI cannot be done within 120 minutes, a fibrinolytic within 30 minutes, then transfer.
  • STEMI with multivessel disease, hemodynamically stable: PCI of significant non-culprit lesions (complete revascularization), at the index procedure or staged, reduces cardiovascular death or MI.
  • STEMI with cardiogenic shock: PCI of the culprit artery only. Routine PCI of non-culprit arteries at the same time is harmful (class 3).
  • NSTE-ACS: invasive angiography; the same anatomy rules then apply. Left main or complex multivessel disease, especially with diabetes, points to CABG.

Clue in the stem, next best step

Clue in the stemWhat it points toNext best step
Stable angina, 80% left main stenosis, good surgical candidateLeft main diseaseCABG
Type 2 diabetes, three-vessel disease including the proximal LADDiabetic multivessel diseaseCABG with a LIMA graft to the LAD
Ischemic cardiomyopathy, LVEF 30%, multivessel diseaseLow ejection fractionCABG plus guideline-directed medical therapy
Single-vessel right coronary disease, normal LVEF, mild angina on one drugLow-risk stable diseaseOptimize medical therapy; PCI only for persistent symptoms
Inferior STEMI, transfer time to a PCI center 3 hoursPCI not available in timeFibrinolysis within 30 minutes, then transfer
Anterior STEMI with shock, two other diseased arteriesCardiogenic shock with multivessel diseaseCulprit-only PCI
Stable STEMI patient after culprit PCI, 80% stenosis in another arteryNon-culprit diseaseStaged or same-procedure PCI of that lesion

Where students lose points

  • Stenting multivessel disease in a patient with diabetes who can have surgery. CABG is preferred.
  • Sending every stable patient with a positive stress test to angiography. Medical therapy comes first unless the anatomy or ejection fraction changes the survival picture.
  • Stenting every narrowed artery during primary PCI in cardiogenic shock.
  • Forgetting the LIMA graft to the LAD, the part of CABG that carries its long-term benefit.
  • Answering PCI for left main disease in a good surgical candidate with complex anatomy.

Practice question

A 61-year-old man with type 2 diabetes and hypertension has exertional chest pressure that has persisted for 4 months despite metoprolol, isosorbide mononitrate, aspirin and atorvastatin. HbA1c is 7.9%. A stress test showed a large area of anterior and lateral ischemia. Coronary angiography shows 85% stenosis of the proximal left anterior descending artery, 80% stenosis of the left circumflex artery and 75% stenosis of the right coronary artery; the left main is normal. Left ventricular ejection fraction is 50%. He has no other major illnesses and is a good surgical candidate.

Which of the following is the most appropriate management?

  1. Continue medical therapy alone
  2. PCI of the left anterior descending artery only
  3. Multivessel PCI with drug-eluting stents
  4. CABG with a left internal mammary artery graft to the LAD
  5. Fibrinolytic therapy
Show the answer

Answer: D. He has diabetes, three-vessel disease involving the proximal LAD and angina that persists on medical therapy, and he can have surgery. CABG with a LIMA graft to the LAD is recommended over PCI in this group to reduce death and repeat revascularization, based on FREEDOM.

Why the others are wrong. A: his angina persists despite good medical therapy, and his anatomy carries a survival argument for CABG. B: incomplete revascularization leaves two diseased arteries. C: multivessel PCI is the option for diabetic patients who are poor surgical candidates. E: fibrinolysis is for STEMI when PCI is not available in time, not for stable disease.

60-second recall

Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.

  1. 1Left main disease
    CABG (class 1); PCI in selected low-complexity anatomy (class 2a).
    Did you get it?
  2. 2Diabetes with multivessel disease
    CABG with LIMA to LAD (FREEDOM).
    Did you get it?
  3. 3Multivessel disease with LVEF 35% or less
    CABG (STICH extension).
    Did you get it?
  4. 4Three-vessel disease with normal LVEF
    Survival benefit only class 2b (ISCHEMIA).
    Did you get it?
  5. 5STEMI with shock
    Culprit-only PCI.
    Did you get it?
  6. 6Stable STEMI with multivessel disease
    Complete revascularization.
    Did you get it?

Next: browse every Board Review post, review anticoagulants vs antiplatelets vs thrombolytics, or see MedRise for students.

Sources

  1. Lawton JS, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. Circulation, 2022 (PubMed 34882435)
  2. American College of Cardiology. Key takeaways from the 2021 coronary revascularization guidelines, 2022
  3. Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. Circulation, 2025 (PubMed 40014670)
  4. Farkouh ME, et al. Strategies for multivessel revascularization in patients with diabetes (FREEDOM). N Engl J Med, 2012 (PubMed 23121323)
  5. Velazquez EJ, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy (STICH extension). N Engl J Med, 2016 (PubMed 27040723)
  6. Maron DJ, et al. Initial invasive or conservative strategy for stable coronary disease (ISCHEMIA). N Engl J Med, 2020 (PubMed 32227755)
  7. Thiele H, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock (CULPRIT-SHOCK). N Engl J Med, 2017 (PubMed 29083953)

MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.

Learned something the hard way on a shelf or on the wards?

Write it up for MedRise Perspectives: 600 to 1,200 words, published under your name, with a decision usually within one day.

Book a free strategy call

Ten minutes to look at your exam date, your scores and what is getting in the way.